A broad-spectrum antiviral targeting entry of enveloped viruses
View/ Open
Author
Wolf, Mike C.
Freiberg, Alexander N.
Zhang, Tinghu
Akyol-Ataman, Zeynep
Grock, Andrew
Hong, Patrick W.
Li, Jianrong
Watson, Natalya F.
Fang, Angela Q.
Aguilar, Hector C.
Porotto, Matteo
Honko, Anna N.
Damoiseaux, Robert
Miller, John P.
Woodson, Sara E.
Chantasirivisal, Steven
Fontanes, Vanessa
Negrete, Oscar A.
Krogstad, Paul
Dasgupta, Asim
Moscona, Anne
Hensley, Lisa E.
Whelan, Sean P.
Faull, Kym F.
Holbrook, Michael R.
Jung, Michael E.
Lee, Benhur
Published Version
https://doi.org/10.1073/pnas.0909587107Metadata
Show full item recordCitation
Wolf, M. C., A. N. Freiberg, T. Zhang, Z. Akyol-Ataman, A. Grock, P. W. Hong, J. Li, et al. 2010. “A Broad-Spectrum Antiviral Targeting Entry of Enveloped Viruses.” Proceedings of the National Academy of Sciences 107 (7): 3157–62. https://doi.org/10.1073/pnas.0909587107.Abstract
We describe an antiviral small molecule, LJ001, effective against numerous enveloped viruses including Influenza A, filoviruses, poxviruses, arenaviruses, bunyaviruses, paramyxoviruses, flaviviruses, and HIV-1. In sharp contrast, the compound had no effect on the infection of nonenveloped viruses. In vitro and in vivo assays showed no overt toxicity. LJ001 specifically intercalated into viral membranes, irreversibly inactivated virions while leaving functionally intact envelope proteins, and inhibited viral entry at a step after virus binding but before virus-cell fusion. LJ001 pretreatment also prevented virus-induced mortality from Ebola and Rift Valley fever viruses. Structure-activity relationship analyses of LJ001, a rhodanine derivative, implicated both the polar and nonpolar ends of LJ001 in its antiviral activity. LJ001 specifically inhibited virus-cell but not cell-cell fusion, and further studies with lipid biosynthesis inhibitors indicated that LJ001 exploits the therapeutic window that exists between static viral membranes and biogenic cellular membranes with reparative capacity. In sum, our data reveal a class of broad-spectrum antivirals effective against enveloped viruses that target the viral lipid membrane and compromises its ability to mediate virus-cell fusion.Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:41483461
Collections
- HMS Scholarly Articles [17928]
Contact administrator regarding this item (to report mistakes or request changes)